However, it is currently a dilemma in China for advanced NSCLC patients with EGFR ex20ins at the time of disease progression on chemotherapy when no validated targeted agents are available, and what's more, chemotherapy has already hit a plateau.8 Here, EGFR is linked to non-small cell lung carcinoma.